Damon Race: Pleased to Share GeneVentiv’s Scientific Debut at ASGCT 2026
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”We’re pleased to share GeneVentiv’s scientific debut at ASGCT 2026.
Our CSO, Paris Margaritis, DPhil, is presenting our work on a next-generation AAV8.FVa construct, advancing a differentiated approach to restoring thrombin generation in hemophilia A patients with or without inhibitors through native hepatic expression of a regulated coagulation cofactor.
The technology presented here forms part of GeneVentiv’s growing IP portfolio.
It’s exciting to reflect on this work as the foundation for our program, which has advanced to studies in hemophilia A canines.
We look forward to sharing additional data as development progresses.”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026